… and anticlonogenic effects of Croton membranaceus M? ll. Arg.(Euphorbiaceae) hydroethanolic root extract in human 22Rv1 castration-resistant prostate cancer cells

KO YEBOAH, M EMOSİVBE… - ACTA Pharmaceutica …, 2023 - actapharmsci.com
… This study employed the 22Rv1 in vitro model of CRPC to investigate the anticancer effect of
… Thus, CMERE possesses anticancer activity against 22Rv1 CRPC model. Keywords: 22Rv1…

ATR inhibition induces CDK1–SPOP signaling and enhances anti–PD-L1 cytotoxicity in prostate cancer

Z Tang, PG Pilié, C Geng, GC Manyam, G Yang… - Clinical Cancer …, 2021 - AACR
antitumor activity in a syngeneic mouse androgen-indifferent, aggressive prostate cancer
model… focused on ATRi therapy activities using a syngeneic prostate cancer model. Analysis of …

Increased Tumor Penetration of Single-Domain Antibody–Drug Conjugates Improves In Vivo Efficacy in Prostate Cancer Models

I Nessler, E Khera, S Vance, A Kopp, Q Qiu, TA Keating… - Cancer research, 2020 - AACR
model, these results demonstrate that smaller monovalent protein scaffolds can increase
tissue penetration enhancing in vivo efficacy in mouse models of prostate cancer. …

Beyond the biomarker role: prostate-specific antigen (PSA) in the prostate cancer microenvironment

A Moradi, S Srinivasan, J Clements, J Batra - Cancer and Metastasis …, 2019 - Springer
… cells and can be used for measuring fPSA synthesis in a xenograft model of castration-resistant
prostate cancer. It has been shown that 89 Zr-5A10 can detect osseous …

225Ac-PSMA-617 for therapy of prostate cancer

C Kratochwil, U Haberkorn, FL Giesel - Seminars in nuclear medicine, 2020 - Elsevier
… been labeled with 213 Bi and demonstrated antitumor activity in an in vitro model for
micrometastatic cancer and in vivo in an LNCaP mouse model 1 ; in these experiments the relative …

Research evidence on high-fat diet-induced prostate cancer development and progression

S Narita, T Nara, H Sato, A Koizumi, M Huang… - Journal of clinical …, 2019 - mdpi.com
prostate cancer cells and animal models to assess the impact of dietary fat on prostate cancer
… the selection of preclinical models and types of dietary intervention. Subcutaneous human …

Orally bioavailable androgen receptor degrader, potential next-generation therapeutic for enzalutamide-resistant prostate cancer

S Ponnusamy, Y He, DJ Hwang, T Thiyagarajan… - Clinical Cancer …, 2019 - AACR
… In preclinical models, UT-34 induced the regression of enzalutamide-resistant tumors at doses
… The anticancer activity of UT-34 in this tumor model was comparable with that observed in …

Discovery of ARD-2585 as an exceptionally potent and orally active PROTAC degrader of androgen receptor for the treatment of advanced prostate cancer

W Xiang, L Zhao, X Han, C Qin, B Miao… - Journal of medicinal …, 2021 - ACS Publications
… preclinical studies as a castration-resistance prostate cancer model. We evaluated a number
of … We next tested the antitumor activity of ARD-2585 in the VCaP xenograft tumor model in …

Docetaxel: An update on its molecular mechanisms, therapeutic trajectory and nanotechnology in the treatment of breast, lung and prostate cancer

M Imran, S Saleem, A Chaudhuri, J Ali… - Journal of Drug Delivery …, 2020 - Elsevier
… DTX the anticancer activity against a wide range of cancers … the radiotherapy in xenografted
prostate tumor model. The … in vivo PC-3 xenografted model. The in vitro results on PC3 …

PD04-07 THE BIVALENT BROMODOMAIN INHIBITOR; MT-1 INHIBITS PROSTATE CANCER GROWTH

S Shukla, M Al-Toubat, C Riveros, AH Feibus… - Journal of …, 2023 - journals.lww.com
… and DOC has greater anti-tumor activity in a model of PCa … anti-tumor activity was also
associated with decreased tumor-induced bone lesions. The mechanism for the anti-tumor activity